Turkish oncologists design customized chemotherapy plans by integrating international ESMO and NCCN guidelines with tumor biology. Specialists utilize molecular profiling and multidisciplinary tumor boards to select specific drug combinations. These protocols account for genetic markers, organ function, and patient performance status.
- Molecular profiling: Specialists analyze HER2, ER/PR receptors, and Ki-67 to target tumor vulnerabilities.
- Genomic testing: Doctors use Oncotype assays to determine if chemotherapy is necessary for borderline cases.
- Multidisciplinary boards: Teams of pathologists, radiologists, and surgeons review cases to align treatment steps.
- Physiological metrics: Dosages are calculated using body surface area and precise liver clearance metrics.
Bookimed Expert Insight: Coordination between internal research and clinical practice is common among top Turkish specialists. For example, Dr. Yesim Yildirim at Anadolu Medical Center has 80+ publications and uses international training from the UK and Israel to apply advanced immunotherapy alongside chemotherapy. This academic background allows doctors to adjust protocols in real-time if a tumor develops resistance.
Patient Consensus: Patients note that their treatment plans often change after the surgical team provides the final pathology report. Many felt relieved when doctors explained that markers like lymph-node status or genomic risk, rather than just stage, drove their specific drug choice. They also appreciate how teams coordinate 24/7 to manage side effects during active cycles.
